SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03. Februar 2022 16:15 ET
|
Scynexis
JERSEY CITY, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS to Participate in Upcoming January Investor Conferences
06. Januar 2022 13:03 ET
|
Scynexis
JERSEY CITY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Reports the Exercise of Warrants Totalling $21.1 Million
22. Dezember 2021 08:30 ET
|
Scynexis
JERSEY CITY, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
BREXAFEMME® (ibrexafungerp tablets) Added to Major National Formulary, Providing Access for Millions More Commercially Insured Patients
20. Dezember 2021 08:30 ET
|
Scynexis
JERSEY CITY, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
European Medicines Agency Grants Orphan Medicinal Product Designation for SCYNEXIS’ Innovative Antifungal Ibrexafungerp for the Indication of Invasive Candidiasis
15. Dezember 2021 08:30 ET
|
Scynexis
Orphan medicinal product designation will provide at least 10 years of market exclusivity in the EU for ibrexafungerp for invasive candidiasis. SCYNEXIS recently was awarded a new patent in the...
SCYNEXIS Announces Agreement with FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis
06. Dezember 2021 07:00 ET
|
Scynexis
SCYNEXIS is initiating a global Phase 3 study to evaluate oral ibrexafungerp as a step-down treatment for invasive candidiasis (IC), including candidemia.Study provides an expeditious path toward...
SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03. Dezember 2021 16:30 ET
|
Scynexis
JERSEY CITY, N.J., Dec. 03, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Reports the Exercise of Warrants Totalling $7.9 Million
03. Dezember 2021 08:43 ET
|
Scynexis
JERSEY CITY, N.J., Dec. 03, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
BREXAFEMME® (Ibrexafungerp Tablets) Receives 2021 Popular Science Best of What’s New Award in the Health Category
01. Dezember 2021 10:37 ET
|
Scynexis
JERSEY CITY, N.J., Dec. 01, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS to Host Ibrexafungerp Hospital Pipeline Update Call and KOL Webcast for Investors on December 6
29. November 2021 08:30 ET
|
Scynexis
JERSEY CITY, N.J., Nov. 29, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...